Quinidine and dihydroquinidine interactions in human plasma
- PMID: 438966
- DOI: 10.1002/jps.2600680414
Quinidine and dihydroquinidine interactions in human plasma
Abstract
The protein-binding characteristics of dihydroquinidine, a known impurity in drug grade quinidine, in human plasma and the effects of dihydroquinidine on quinidine interactions with these plasma constituents were studied by equilibrium dialysis. In the plasma concentration range of 1.75-23.0 mg/liter, dihydroquinidine binding was similar to the binding observed with quinidine. The data suggested the presence of a single class of binding sites for both compounds in the plasma drug concentration range and samples studied. The mean values for the association constant, K, and the total concentration of binding sites, nPt, for dihydroquinidine were 4.75 +/- 0.67 X 10(4) M-1 and 5.78 +/- 0.17 x 10(-5) M, respectively. The corresponding values for quinidine were 4.78 +/- 1.00 x 10(4) M-1 and 5.65 +/- 0.48 x 10(-5) M. In the presence of 5 and 10% (of total alkaloid content) dihydroquinidine, the plasma concentration of unbound quinidine did not change significantly. At a 20% level of dihydroquinidine, however, an increase in unbound quinidine was observed (p less than 0.05). The elevations in free quinidine concentrations were directly related to the level of dihydroquinidine present. The results of this study indicate that the interactions between dihydroquinidine and quinidine for binding sites on human plasma proteins are competitive.
Similar articles
-
Effects of dihydroquinidine on in vitro and in vivo quinidine disposition.Biochem Pharmacol. 1980 Mar 1;29(5):737-40. doi: 10.1016/0006-2952(80)90549-3. Biochem Pharmacol. 1980. PMID: 20227949
-
Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes.Clin Pharmacol Ther. 1988 Jun;43(6):636-42. doi: 10.1038/clpt.1988.88. Clin Pharmacol Ther. 1988. PMID: 3378385
-
[Plasma protein binding of 3-(S) or 3-(R) hydroxylated derivatives of quinidine and dihydroquinidine].Therapie. 1986 May-Jun;41(3):159-62. Therapie. 1986. PMID: 3750253 French. No abstract available.
-
Protein binding in antiretroviral therapies.AIDS Res Hum Retroviruses. 2003 Sep;19(9):825-35. doi: 10.1089/088922203769232629. AIDS Res Hum Retroviruses. 2003. PMID: 14585213 Review.
-
Drug interactions involving the displacement of drugs from plasma protein and tissue binding sites.Pharmacol Ther. 1982;17(2):211-20. doi: 10.1016/0163-7258(82)90012-2. Pharmacol Ther. 1982. PMID: 6757977 Review. No abstract available.
Cited by
-
High-throughput analysis of drug dissociation from serum proteins using affinity silica monoliths.J Sep Sci. 2011 Aug;34(16-17):2255-63. doi: 10.1002/jssc.201100280. Epub 2011 Jun 10. J Sep Sci. 2011. PMID: 21661111 Free PMC article.
-
Absorption of quinidine and dihydroquinidine in humans.Eur J Clin Pharmacol. 1981;21(3):195-9. doi: 10.1007/BF00627920. Eur J Clin Pharmacol. 1981. PMID: 7318878
-
Analysis of free drug fractions in human serum by ultrafast affinity extraction and two-dimensional affinity chromatography.Anal Bioanal Chem. 2016 Jan;408(1):131-40. doi: 10.1007/s00216-015-9082-7. Epub 2015 Oct 13. Anal Bioanal Chem. 2016. PMID: 26462924 Free PMC article.
-
Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration.Eur J Clin Pharmacol. 1979 Sep;16(2):101-5. doi: 10.1007/BF00563115. Eur J Clin Pharmacol. 1979. PMID: 499305
-
Entrapment of alpha1-acid glycoprotein in high-performance affinity columns for drug-protein binding studies.J Chromatogr B Analyt Technol Biomed Life Sci. 2016 May 15;1021:188-196. doi: 10.1016/j.jchromb.2015.11.021. Epub 2015 Nov 27. J Chromatogr B Analyt Technol Biomed Life Sci. 2016. PMID: 26627938 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources